key: cord-0888537-lublcbuz
authors: Huang, Alice; Cicin-Sain, Caroline; Pasin, Chloe; Epp, Selina; Audigé, Annette; Müller, Nicolas J; Nilsson, Jakob; Bankova, Andriyana; Wolfensberger, Nathan; Vilinovszki, Oliver; Nair, Gayathri; Hockl, Philipp; Schanz, Urs; Kouyos, Roger D.; Hasse, Barbara; Zinkernagel, Annelies S.; Trkola, Alexandra; Manz, Markus G.; Abela, Irene A.; Müller, Antonia M.S.
title: Antibody Response to SARS-CoV-2 Vaccination in Patients Following Allogeneic Hematopoietic Cell Transplantation
date: 2022-01-31
journal: Transplant Cell Ther
DOI: 10.1016/j.jtct.2022.01.019
sha: 0c19d567de416a27c6ee6218031872407c466976
doc_id: 888537
cord_uid: lublcbuz

BACKGROUND: Vaccines against SARS-CoV-2 have been rapidly approved. While pivotal studies were conducted in healthy volunteers, little information is available on safety and efficacy of mRNA vaccines in immunocompromised patients, including recipients of allogeneic hematopoietic cell transplantations (allo-HCT). OBJECTIVES: Here, we used a novel assay to analyze patient- and transplant-related factors and their influence on immune responses over an extended period of time (up to 6 months) to the SARS-CoV-2 vaccination in a large and homogenous group of allo-HCT recipients at a single center in Switzerland. STUDY DESIGN: We examined longitudinal antibody responses to SARS-CoV-2 vaccination with BNT162b2 (BioNTech/Pfizer) or mRNA-1273 (Moderna) in 110 allo-HCT recipients and 86 healthy controls. Seroprofiling recording IgG, IgA, and IgM reactivities against SARS-CoV-2 antigens (receptor-binding domain (RBD), spike glycoprotein subunits S1 and S2, and nucleocapsid protein (N)) was performed prior to vaccination, prior to the 2(nd) dose, and 1, 3, and 6 months (m) after the 2(nd) dose. Patients were stratified to three groups (A) 3-6m post HCT; (B) 6-12m post HCT; and (C) >12m post HCT. RESULTS: Individuals early post allo-HCT (3-6 and 6-12m post HCT) developed significantly lower antibody titers after vaccination compared to patients >12m post allo-HCT and healthy controls (p<0.001). Within the cohort of HCT recipients, patients >65 years (p=0.030), those under immunosuppression for prevention or treatment of graft-vs-host disease (GVHD) (p=0.033), and/or with relapsed disease (p=0.014) displayed poor humoral immune response to the vaccine. In contrast, the intensity of the conditioning regimen, underlying disease (myeloid/lymphoid/other), and presence of chronic GVHD had no impact on antibody levels. Antibody titers achieved the highest levels 1m after the 2(nd) dose of the vaccine but substantially waned in all transplanted groups and healthy controls over time. CONCLUSIONS: This analysis of long-term vaccine antibody response is of critical importance to allo-HCT recipients and transplant physicians to guide treatment decisions regarding re-vaccination and social behavior during the SARS-CoV-2 pandemic.

 Allo-HCT recipients display impaired immune responses to SARS-CoV-2 vaccination.

 Vaccination resulted only in weak immunity in patients <12m post allo-HCT.

 Patients >65y and/or immunosuppression displayed lowest responses to vaccination. immunosuppression >14 days within the past 6 months (m) or those given immunoglobulins or blood products within the past 3m were excluded from the phase 3 trial for mRNA-1273. 6 Despite the presumption that immune responses to the SARS-CoV-2 vaccines may be heterogeneous in patients following allogeneic hematopoietic cell transplantation (allo-HCT) the European Society of Blood and Marrow Transplantation (EBMT) and the American Society of Hematology (ASH) recommend the administration of the vaccine as early as 3m after allo-HCT, including patients with controlled graft-versus-host disease (GVHD). 7 It is still unclear, whether HCT recipients are able to develop a substantial immune response after mRNA vaccination. Moreover, the influence of simultaneous IST, presence of GVHD, and/or other patient-or transplant-related parameters on the level and temporal dynamics of immune protection against SARS-CoV- 2 have not yet been elucidated. Here, we report the results of a prospective observational study on the efficacy of SARS-CoV-2 vaccination among 110 allo-HCT recipients and 86 healthy controls. This study is a prospective single center observational study   with a healthy control group recruited from hospital and university 

Longitudinal humoral response to SARS-CoV-2 was measured by using the immunoassay ABCORA. 9 The assay measures IgG, IgA, and IgM reactivity to four SARS-CoV-2 antigens, the receptor-binding domain (RBD), spike glycoprotein subunits S1 and S2, and nucleocapsid protein (N), characterizing a total of 12 SARS-CoV-2 parameters. Details are provided in the supplementary material.

Samples were also evaluated with the Elecsys ® Anti-SARS-CoV-2 S assay (Roche Diagnostics GmbH). This ECLIA immunoassay was used according to the manufacturer's instructions.

SARS-CoV-2 pseudo-neutralization assay: SARS-CoV-2 plasma neutralization activity was recorded using a HIV-based pseudovirus system as described. 9, 10 Details are provided in the supplementary material.

The sum of S1 signal over cut-off (SOC) values (sum S1), defined as the sum of IgG, IgA, and IgM S1 SOC values, can be used to predict the neutralization status of a patient using a logistic regression previously developed in a cohort of 467 infected individuals. 9 A sum S1 value > 17 is predictive of a neutralization titer NT50>250, with a specificity of 94% and a sensitivity of 67%. 

A total of 110 allo-HCT patients with a median age of 57 years (interquartile range: 46-65 years)

were enrolled ( patients, relapse (n=6), sepsis due to intensive IST for chronic GVHD (n=1) and unknown cause (n=1)).

A total of 86 healthy controls with a median age of 35.5 years (range 23-64 years) were enrolled.

Compared to the patient cohort, the healthy cohort included younger and more female participants (76.7%). The majority of healthy controls (87%) received BNT162b, whereas only 11 healthy controls received mRNA-1273.

In our cohort, 5/86 healthy controls had already seroconverted asymptomatically prior to vaccination and 10/106 patients experienced previous SARS-COV-2 infection (7 of them were seropositive at baseline). The 2-dose vaccination regimen was maintained for these patients, and they were included in the analysis.

Allo-HCT patients tolerated the SARS-CoV-2 vaccines well and no severe complications were observed. Local pain at the injection site was most commonly reported, followed by myalgia and headaches. Forty percent of patients had no side effects at all (supplemental table 1 ). Of note, two patients developed chronic GVHD of the lung during follow-up after vaccination.

We longitudinally assessed humoral immune responses against four antigens of SARS-CoV-2 (RBD. S1, S2 and N, figure 2A and supplemental figure S1-2), up to 6 months after the 2 nd vaccine injection. Response in the healthy controls group was homogeneous: as expected 11 , we observed the highest antibody responses 1m after the 2 nd injection and a decline of antibody titers thereafter.

Among allo-HCT recipients, antibody responses were more heterogeneous, as some (especially those 3-6m and 6-12m after HCT) did not mount a response even after full vaccination.

Determining the neutralization activity of the measured antibody binding response is decisive to ascertain protective immunity after vaccination. Assessment with ABCORA allows predicting whether infected individuals develop high (NT50>250) or no/low neutralization titers (NT50<250) by the sum of S1 signal over cut-off (SOC) values for IgG, IgA, IgM (sum S1). 9 To corroborate the neutralization prediction model after vaccination, we measured neutralization activity in allo-HCT recipients and healthy controls in a pseudovirus-neutralization assay. Healthy controls displayed significantly higher titers than patients (p<0.001 for 3-6m, 6-12, and >12m, supplemental figure  S3A ). Furthermore, we confirmed the reliable neutralization prediction after vaccination (AUC= 0.99, supplemental figure S3B) and hence used the same sum S1 threshold of 17 to predict neutralization in our cohort (supplemental figure S3C ). At T1, the majority of patients early post allo-HCT (3-6m and 6-12m after HCT) showed significantly lower sum S1 responses compared to those > 12m post allo-HCT (p=0.001 and p=0.006 for 3-6m and 6-12m versus >12m, respectively; figure 2B ).

Moreover, 70% of transplant recipients (71/101) and 22% of healthy controls (n=16/74) did not reach the neutralization threshold (sum S1=17), highlighting the importance of two vaccine doses. At T2, We assessed antibody decline after T2 by using a single exponential decline model ( figure 2F ) and estimated the sum S1 half-life (t1/2=67 days, 95% confidence interval [62-74]). This value, although lower than the estimated half-life of antibodies after infection, is in line with recent observations of increased likelihood of breakthrough infection with longer time since mRNA vaccination. [12] [13] [14] We also performed Elecsys S test on a subset of samples. 9 The results in both assay systems correlated well at all three time points (T1-T3) (correlation coefficients between 0.93 and 0.95, supplemental figure S4A ). Similar patterns were observed, with significantly lower anti-RBD antibody response in patients 3-6 and 6-12m post-HCT versus >12m post-HCT, and the highest response in healthy controls (supplemental figure S4B ).

We further differentiated the influence of time since allo-HCT on antibody binding features at T2 (2-6 weeks post 2 nd dose) and were able to identify three distinct groups of patients segregating mainly based on IgG and IgA spike response in an unsupervised clustering algorithm (figure 3A): the most distinctive group (Cluster 1) of patients was characterized by the simultaneous presence of high RBD, S1, and S2 IgG and some IgA and IgM binding and contained mostly >12m post allo-HCT patients and healthy controls. Cluster 2 was more heterogeneous, with individuals from all groups (transplanted and healthy controls), showing a robust RBD and S1 IgG response but low to no IgA, IgM, and IgG S2 responses. Cluster 3 contained only transplanted patients with low antibody response (almost all patients from groups 3-6 and 6-12m, and some from >12m post-HCT), including low IgG RBD and S1 titers. We confirmed that patients >12m allo-HCT clustered mostly with healthy controls based on their humoral antibody response to SARS-CoV-2 vaccine by a principal component analysis (PCA) ( figure 3B ).

We employed a multivariate linear regression predicting the sum S1 value at T2, adjusted on age, , table 1) .

Within the allo-HCT cohort we further evaluated the associations of age, gender, preinfection, intensity of the conditioning regimen (reduced intensity, RIC; vs. myeloablative, MAC), chronic GVHD, immunosuppressive treatment (IST), and relapse to identify distinct risk factors for impaired humoral immunity after vaccine. In the applied multivariate regression model we grouped patients 3-6 and 6-12m post-HCT, as they showed similar low levels of sum S1 in the prior analysis ( figure 3C ).

Reduced predicted neutralizing titers (sum S1) at T2 were significantly associated with (i) whether 

Characterizing low responders that do not reach the neutralization threshold of 17 after vaccination is of utmost clinical importance. We identified a total of 38 low responders in our cohort (17 patients were 3-6m, 8 were 6-12m and 13 were >12m post allo-HCT). Overall, a high proportion of patients 3-12m after transplant were on IST (75%), and the proportion of low responders in this group was consistently high, whether patients were on IST or not (70% off IST, 60% on IST). In contrast, only 28% of patients in group >12m were on IST, and the low responders constituted a higher proportion of those on IST (35%) versus those not on IST (16%) (figure 5A). Adding an interaction term between the variables "group" and "IST" did not improve our multivariate linear regression and was not significant (p=0.42). By assessing age categories, we observed consistent patterns: the proportion of low responders was higher in patients under IST regardless of their age and was also generally higher in older patients (figure 5B). We vaccinated low responders with a third dose and evaluated the response approximately 1 month after the third dose (median 36 days, IQR:31-37 days) in 23 patients (7 died, 1 was lost of follow-up, 1 was excluded because the patient received a booster vaccination 3 months after the second, 1 refused to receive a booster injection and for the 5 others booster titers were not available yet). For these 23 patients, the third dose had been received around 6 months after the second dose (median: 197 days, 1Q-3Q: 138-221 days). We documented an increase of the humoral response in a fraction of patients: 47% (9/19) of the group 3-12m and 25% (1/4) of the group >12m developed a humoral immune response and became responders (sum S1>17) after the third dose ( figure 5C ). Of those that still did not respond to the third dose, 46% table 3) .

Regeneration of the adaptive immune system requires weeks to months following allo-HCT. Initially, adoptively co-transferred mature lymphocytes expand, but over time (weeks to months) nascent, donor hematopoietic stem cell (HSC)-derived T and B cells develop. Figure 6A displays the dynamics of the recovery of total B cells, recent thymic emigrants (RTE), naïve and memory CD4 + and CD8 + T cells in the blood, demonstrating that reconstitution of the adaptive immune system post allo-HCT requires years rather than months, with the majority of patients reaching normal levels of B and T cells only beyond 12m post-HCT. Antibody response to the SARS-CoV-2 vaccine significantly correlated with higher B cell counts in the blood (figure 6B, upper left panel), but also higher RTE, naïve CD4 + and naïve CD8 + cells, and memory CD4 + cells.

Infections are a major cause of death in patients who have undergone allo-HCT, and several studies have confirmed an increased risk of morbidity and mortality for COVID-19. 3,15-18 Accordingly, this vulnerable population has been granted prioritized access to SARS-CoV-2 vaccines after their

approval. Yet, the efficacy of vaccinations in general, is often insufficient, inconsistent, and unpredictable. 19, 20 In addition to immunosuppressive agents, GVHD can cause severe immune dysfunction, and in particular B lymphopenia with hypogammaglobulinemia can persist for years. 21 Our study adds valuable information to recently published reports: We analyzed longitudinal antibody responses after SARS-CoV-2 vaccination in a relatively large allo-HCT cohort (n=110), revealing both antibody peaks and their significant temporal decline over 6m post vaccination. We examined and adjusted for various transplant-related factors, including the intensity of the conditioning regimen, chronic GVHD, IST, and relapse.

Patients older than 65 years of age and those early after transplantation were the subgroups with the highest risk of failing to respond sufficiently to two vaccine doses, but IST also had an impact on immune function. The lower rate of seroconversion to SARS-CoV-2 and other vaccines in elderly patients is consistent with prior reports. 22 Likewise, detrimental effects of IST on immune responses to the SARS-CoV-2 vaccine have been described in solid organ transplant recipients. 8 Patients in our study were given IST either because they were early post-HCT (prophylactic IST), or because they were suffering from GVHD (therapeutic IST). Whether a 3 rd booster dose of the vaccine may overcome low responses remains to be elucidated in the coming months, but first experiences (including our own observations) indicate that low responders can benefit from a 3 rd dose and turn to good responders subsequently. Unexpectedly, chronic GVHD per se was not associated with lower antibody levels in our patient cohort. Chronic GVHD is a very heterogeneous condition affecting one or several organs. Depending on the number and type of involved organs, treatment can be topical or may require single-agent or combined systemic IST. Moreover, "subclinical" GVHD of the bone marrow and lymphoid tissues can result in severe lymphopenia and immune dysfunction. 21, 23, 24 In our current study, cohort subgroups of chronic GVHD were too small to perform statistical analyses.

However, we observed a substantial proportion of low responders to the vaccine were patients with chronic GVHD on systemic IST, including calcineurin-inhibitors, steroids, but also novel agents such as ruxolitinib. Recent phase 3 studies demonstrated efficacy of the STAT1/2 inhibitor for chronic GVHD. 25 Impaired response to BTN162b2 under treatment with ruxolitinib has also been observed in non-transplant patients confirming the highly immunosuppressive effect of this agent. 26 Finally, in our study, patients treated for relapse of their underlying disease had poor humoral immune responses.

This finding is, again, consistent with observations by others, in which hematological patients under systemic cytotoxic or immune modulatory treatments developed only low to no serological responses to the vaccine. 26 Our findings are in line with low anti-SARS-CoV-2 antibody response observed in a recently published study on patients with cancer including hematological malignancies. 27 In this report, positive anti-S IgG titers were measurable in 94% of healthy controls, but only 18% of patients with A large cohort of patients (n=885) with hematological malignancies in Lithuania included 122 allo-HCT-recipients. 26 Compared with patients on treatment with Bruton kinase inhibitors, ruxolitinib, venetoclax, or anti-CD20 antibody therapy, patients following allo-HCT were amongst those with the highest levels of antibody titers against SARS-CoV-2 following BNT162b vaccination. Consistent with our observations, the Lithuanian study found low antibody responses in the few patients early post HCT (<6 months, n=5; n=13 for 6-12m).

Our study is limited by the single center character and control group of healthy individuals that differed significantly in age and sex from our patient cohort, what may have hindered detecting the recently described influence of sex on vaccine efficacy. 30[Preprint] Furthermore, due to the lack of an established assay to measure T-cell responses to the SARS-CoV-2 vaccine at our center we were not able to analyze cellular immunity. Emerging data on quantifications of SARS-CoV-2-specific T cells and corresponding cytokine production upon exposure to specific peptides in vitro stress the importance and role of T-cell mediated immunity against SARS-CoV-2, but also reveal a wide heterogeneity of the magnitude of such T-cell responses. Hence, ultimately both humoral and cellular immunity should be integrated into assessments that define the correlates of protection necessary to evaluate current vaccine strategies. [31] [32] [33] [34] In conclusion, in the light of breakthrough infections in vaccinated individuals systematic analyses of immune responses to the SARS-CoV-2 vaccines and their temporal dynamics are urgently warranted to guide treatment decisions during this pandemic. Our results highlight the importance of identifying those at highest risk with longitudinal antibody assessment and moreover elucidates the rapid decline of vaccine efficacy not only in high risk patients but also in healthy individuals.

 Alice Huang: performed and designed research, was involved in patient recruitment, collected data, analyzed and interpreted data, wrote the manuscript  Caroline Cicin-Sain: performed and designed research, was involved in patient recruitment, collected data, analyzed and interpreted data, wrote the manuscript  Chloe Pasin: analyzed and interpreted data, performed statistical analysis, wrote the manuscript  Selina Epp: conducted binding and neutralization experiments  Annette Audige: conducted binding experiments, critically reviewed and edited the manuscript  Nicolas J Müller: designed research, critically reviewed and edited the manuscript  Jakob Nilsson: designed research, critically reviewed and edited the manuscript  Andriyana Bankova: was involved in patient recruitment, critically reviewed and edited the manuscript  Nathan Wolfensberger: was involved in patient recruitment, critically reviewed and edited the manuscript  Oliver Vilinovszki: was involved in patient recruitment, critically reviewed and edited the manuscript  Gayathri Nair: was involved in patient recruitment, critically reviewed and edited the manuscript  Philipp Hockl: was involved in patient recruitment, critically reviewed and edited the manuscript  Urs Schanz: critically reviewed and edited the manuscript  Roger D. Kouyos: critically reviewed and edited the manuscript  Barbara Hasse: was involved in patient recruitment and vaccination, critically reviewed and edited the manuscript  Zinkernagel Annelies S.: critically reviewed and edited the manuscript  Alexandra Trkola: critically reviewed and edited the manuscript  Markus G. Manz: critically reviewed and edited the manuscript  Irene A. Abela: performed and designed research, collected data, conducted binding and neutralization experiments, analyzed and interpreted data, wrote the manuscript  Antonia M.S. Müller: performed and designed research, was involved in patient recruitment, collected data, analyzed and interpreted data, wrote the manuscript

All the authors have no conflict of interests to declare.

Parts of the study were funded by the pandemic fond, UZH foundation.

The cantonal ethics committee Zurich approved the study on the 9 th March 2021 (BASEC No. 2021-00261). 

Data collected for the study, including de-identified participant data, and data dictionary or other related documents (eg, informed consent form) will be made available to others upon request. These data will be shared with researchers who provide a methodologically sound proposal to achieve aims in the approved proposal. The data will be available beginning 3 months and ending 36 months following publication. Proposals should be directed to irene.abela@usz.ch; data requestors will need to sign a data access agreement. 

WHO Coronavirus (COVID-19) Dashboard

Swissmedic grants authorisation for the COVID-19 vaccine from Moderna

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. The Lancet Haematology

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

COVID-19 vaccines

Antibody Response to 2-Dose SARS-CoV-2

mRNA Vaccine Series in Solid Organ Transplant Recipients

Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. The Lancet

Antibody titers against SARS-CoV-2 decline, but do not disappear for several months

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort

The Burden of Bacterial and Viral Infections in Hematopoietic Stem Cell Transplant

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation

COVID-19 outcomes in patients with hematologic disease

COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter

How I vaccinate blood and marrow transplant recipients

Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients

Reconstitution of the immune system after hematopoietic stem cell transplantation in humans

Why Aging T Cells Fail: Implications for Vaccination

Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation

Co-transplantation of pure blood stem cells with antigen-specific but not bulk T cells augments functional immunity

Ruxolitinib for Glucocorticoid-Refractory Chronic Graftversus-Host Disease

COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study

Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study. The Lancet

Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses

Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients

Grey shaded areas correspond to normal ranges for each cell subpopulation. (B) Correlation of immune reconstitution and sum S1 values at T2 in allo-HCT patients stratified by time between transplant and vaccination